查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108372

幹細胞療法市場分析及預測（至2035年）：依類型、產品、服務、技術、應用、流程、最終使用者、模式及階段分類

Stem Cell Therapy Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球幹細胞治療市場預計將從2025年的134億美元成長到2035年的443億美元，CAGR為12.7%。該成長主要得益於法規核准的增加和再生醫學的日益普及。據美國食品藥物管理局（FDA）表示，2024年12月，Ryoncil（Remestem Cell-L）成為首個獲得FDA批准用於治療兒童類固醇抗藥性急性移植物抗宿主疾病（SR-aGVHD）的間質幹細胞療法。這項里程碑式的批准有望加速幹細胞研究、商業化以及下一代再生醫學的發展。

幹細胞治療市場按「類型」細分，包括異體幹細胞治療、自體幹細胞治療、同基因幹細胞治療和其他類型。其中，自體幹細胞治療因其免疫排斥風險低、患者相容性高等優勢，佔了較大的市場佔有率。它廣泛應用於再生醫學、腫瘤學和血液學領域。異體幹細胞治療由於其可擴展性、供體來源細胞的易得性以及在先進細胞療法中日益普及，正呈現強勁成長動力。同基因幹細胞治療主要用於研究和特殊應用，使用基因相同的供體和受體。幹細胞處理、增殖和再生醫學的進步推動所有類型療法的創新。

市場區隔
類型 同種、自體、同基因、其他
產品 成體幹細胞、胚胎幹細胞、誘導性富潛能幹細胞、造血幹細胞、間質幹細胞、神經幹細胞、羊膜幹細胞、其他
服務 幹細胞庫、幹細胞處理、幹細胞鑑定、其他
技術 細胞收集、細胞生產、冷凍保存、增殖和繼代培養以、其他
用途 再生醫學、整形外科、神經病學、循環系統、腫瘤學、血液學、傷口護理、糖尿病、其他
過程 體內、體內、其他
最終用戶 醫院、診所、研究機構、生技公司、其他
模式 侵入性、非侵入性、其他
階段 臨床前研究、臨床試驗、商業化、其他

幹細胞治療市場的終端使用者包括醫院、診所、研究機構、生技公司等。由於幹細胞療法在癌症、整形外科疾病、骨科疾病以及再生醫學等領域的應用日益廣泛，醫院已成為主要的終端使用者群體。生物技術公司透過投資細胞療法、臨床試驗和開發創新幹細胞產品，推動市場成長。研究機構透過幹細胞研究、疾病模型建構和治療方法發現，做出了重要貢獻。隨著專業幹細胞治療中心和門診治療方案的增加，診所的角色也不斷擴大。醫療保健領域投資的增加和個人化醫療的進步，進一步推動了所有終端用戶群的市場成長。

區域概覽

到2025年，北美佔據全球幹細胞治療市場最大佔有率，這主要得益於其先進的醫療基礎設施、強大的再生醫學生態系統以及對幹細胞研發的大量投資。該地區匯聚了許多領先的生物技術和製藥公司、研究機構以及專業治療中心，這些機構正積極開發用於治療癌症、神經系統疾病、心血管疾病、整形外科疾病和自體免疫疾病的幹細胞療法。政府的大力資助、對再生醫學的有利監管支持以及臨床試驗數量的增加，加速創新幹細胞療法的商業化。此外，個人化醫療的日益普及以及細胞處理和製造技術的進步，將繼續鞏固北美在全球幹細胞治療市場的主導地位。

亞太地區預計將成為幹細胞治療市場成長最快的地區，這主要得益於生物技術和再生醫學研究的拓展、醫療保健領域投資的增加以及政府對先進細胞療法的大力支持。中國、日本、韓國、印度和新加坡等國家正透過國家資助計畫、有利的監管改革和擴大臨床試驗活動來增強其幹細胞研究能力。慢性病和退化性疾病的日益普遍、對個人化再生療法的需求不斷成長以及對細胞治療生產設施投資的增加，都進一步推動了該地區的市場擴張。此外，學術機構、生物技術公司和醫療服務提供者之間的合作，以及醫療基礎設施的改善和醫療旅遊業的蓬勃發展，預計將使亞太地區在預測期內成為成長最快的區域市場。

主要趨勢和促進因素

再生醫學和先進幹細胞療法的拓展

幹細胞治療市場正呈現強勁的發展趨勢，包括利用誘導多功能細胞（iPS細胞）、間質幹細胞（MSCs）和基因修飾細胞的先進再生醫學解決方案。生技和製藥公司正日益關注幹細胞平台，以治療以往難以治癒的疾病，例如神經系統疾病、心血管疾病、整形外科損傷和自體免疫疾病。細胞工程、基因編輯、生物材料和可擴展細胞生產技術的進步提高幹細胞療法的安全性和有效性。此外，創新細胞療法臨床試驗的增加和法規核准範圍的擴大加速幹細胞治療解決方案的商業化。

慢性病盛行率不斷上升，以及對再生醫學的需求日益成長

慢性疾病的日益普遍以及對再生醫學治療方案需求的不斷成長是幹細胞治療市場的主要驅動力。癌症、脊髓損傷、糖尿病和退化性疾病等疾病使得修復受損組織和恢復生物功能的療法需求顯著增加。製藥公司、生技公司和研究機構不斷增加投資，推動了幹細胞產品的研發和臨床應用。此外，個人化醫療的進步、幹細胞庫基礎設施的建設以及政府對再生醫學研究支持力度的加大，也促進了幹細胞療法在全球醫療保健系統中的應用。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 同種
    • 自體
    • 同基因
    • 其他
  • 市場規模及預測：依產品分類
    • 成體幹細胞
    • 胚胎幹細胞
    • 誘導性富潛能幹細胞
    • 造血幹細胞
    • 間質幹細胞
    • 神經幹細胞
    • 羊膜幹細胞
    • 其他
  • 市場規模及預測：依應用領域分類
    • 再生醫學
    • 整形外科
    • 神經病學
    • 循環系統
    • 腫瘤學
    • 血液學
    • 傷口護理
    • 糖尿病
    • 其他
  • 市場規模及預測：依技術分類
    • 細胞收集
    • 細胞生產
    • 冷凍保存
    • 增殖和繼代培養
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 研究機構
    • 生技公司
    • 其他
  • 市場規模及預測：依製程分類
    • 體內
    • 體外
    • 其他
  • 市場規模及預測：依服務分類
    • 幹細胞庫
    • 幹細胞處理
    • 幹細胞特徵分析
    • 其他
  • 市場規模及預測：依階段分類
    • 臨床前
    • 臨床試驗
    • 商業化
    • 其他
  • 市場規模及預測：依模式
    • 侵入性
    • 非侵入性
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Mesoblast
  • Athersys
  • Fate Therapeutics
  • Pluristem Therapeutics
  • Osiris Therapeutics
  • StemCells Inc
  • Cytori Therapeutics
  • Vericel Corporation
  • BrainStorm Cell Therapeutics
  • Caladrius Biosciences
  • Gamida Cell
  • Astellas Pharma
  • BioTime Inc
  • ReNeuron Group
  • Cellular Biomedicine Group
  • Lineage Cell Therapeutics
  • Stempeutics Research
  • Cynata Therapeutics
  • Anterogen
  • ViaCyte

第9章 關於我們

簡介目錄
Product Code: GIS20398

The global Stem Cell Therapy Market is projected to grow from $13.4 billion in 2025 to $44.3 billion by 2035, at a compound annual growth rate (CAGR) of 12.7%. The stem cell therapy market is driven by increasing regulatory approvals and growing adoption of regenerative medicine. According to the U.S. FDA, Ryoncil (remestemcel-L) became the first FDA-approved mesenchymal stromal (stem) cell therapy in December 2024 for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients. This landmark approval is expected to accelerate stem cell research, commercialization, and the development of next-generation regenerative therapies.

The Type segment of the Stem Cell Therapy Market includes allogeneic, autologous, syngeneic, and others. Among these, autologous stem cell therapy holds a significant market share due to its advantages, including reduced risk of immune rejection and improved compatibility with patients. It is widely used in regenerative medicine, oncology, and hematological applications. Allogeneic stem cell therapy is witnessing strong growth due to its scalability, availability of donor-derived cells, and increasing adoption in advanced cell-based treatments. Syngeneic therapies are primarily used in research and specialized applications involving genetically identical donor and recipient models. Growing advancements in stem cell processing, expansion technologies, and regenerative medicine are driving innovation across all therapy types.

Market Segmentation
TypeAllogeneic, Autologous, Syngeneic, Others
ProductAdult Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells, Hematopoietic Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Amniotic Stem Cells, Others
ServicesStem Cell Banking, Stem Cell Processing, Stem Cell Characterization, Others
TechnologyCell Acquisition, Cell Production, Cryopreservation, Expansion and Sub-Culture, Others
ApplicationRegenerative Medicine, Orthopedic, Neurology, Cardiovascular, Oncology, Hematology, Wound Healing, Diabetes, Others
ProcessIn-Vivo, Ex-Vivo, Others
End UserHospitals, Clinics, Research Institutes, Biotechnology Companies, Others
ModeInvasive, Non-Invasive, Others
StagePreclinical, Clinical Trials, Commercialization, Others

The End User segment of the Stem Cell Therapy Market includes hospitals, clinics, research institutes, biotechnology companies, and others. Hospitals represent a major end-user segment due to the increasing adoption of stem cell therapies for treating cancer, blood disorders, orthopedic conditions, and regenerative medicine applications. Biotechnology companies are driving market growth through investments in cell-based therapies, clinical trials, and development of innovative stem cell products. Research institutes contribute significantly through stem cell research, disease modeling, and therapeutic discovery. Clinics are expanding their role with the growing availability of specialized stem cell treatment centers and outpatient procedures. Increasing healthcare investments and advancements in personalized medicine are further supporting market growth across end-user segments.

Geographical Overview

North America accounted for the largest share of the global stem cell therapy market in 2025, driven by its advanced healthcare infrastructure, strong regenerative medicine ecosystem, and substantial investments in stem cell research and clinical development. The region is home to leading biotechnology and pharmaceutical companies, research institutions, and specialized treatment centers actively developing stem cell therapies for oncology, neurological disorders, cardiovascular diseases, orthopedic conditions, and autoimmune diseases. Strong government funding, favorable regulatory support for regenerative medicine, and increasing clinical trials have accelerated the commercialization of innovative stem cell therapies. Furthermore, the growing adoption of personalized medicine and advancements in cell processing and manufacturing technologies continue to reinforce North America's leadership in the global stem cell therapy market.

Asia Pacific is expected to register the highest growth in the stem cell therapy market owing to expanding biotechnology and regenerative medicine research, increasing healthcare investments, and growing government support for advanced cell-based therapies. Countries such as China, Japan, South Korea, India, and Singapore are strengthening their stem cell research capabilities through national funding programs, favorable regulatory reforms, and expanding clinical trial activities. Rising prevalence of chronic and degenerative diseases, increasing demand for personalized regenerative treatments, and growing investments in cell therapy manufacturing facilities are further driving regional market expansion. Moreover, collaborations between academic institutions, biotechnology companies, and healthcare providers, along with improving healthcare infrastructure and increasing medical tourism, are expected to position Asia Pacific as the fastest-growing regional market during the forecast period.

Key Trends and Drivers

Increasing Development of Regenerative Medicine and Advanced Stem Cell-Based Therapies:

The Stem Cell Therapy Market is witnessing a strong trend toward the development of advanced regenerative medicine solutions, including induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and engineered cell-based therapies. Biotechnology and pharmaceutical companies are increasingly focusing on stem cell platforms to treat previously challenging conditions such as neurological disorders, cardiovascular diseases, orthopedic injuries, and autoimmune disorders. Advancements in cell engineering, gene editing, biomaterials, and scalable cell manufacturing technologies are improving the safety and effectiveness of stem cell therapies. Additionally, increasing clinical trials and regulatory approvals for innovative cell-based treatments are accelerating the commercialization of stem cell therapy solutions.

Rising Prevalence of Chronic Diseases and Growing Demand for Regenerative Treatments:

The increasing prevalence of chronic diseases and the growing need for regenerative treatment options are major drivers of the Stem Cell Therapy Market. Conditions such as cancer, spinal cord injuries, diabetes, and degenerative disorders have created significant demand for therapies capable of repairing damaged tissues and restoring biological functions. Rising investments from pharmaceutical companies, biotechnology firms, and research institutions are supporting the development of stem cell-based products and clinical applications. Furthermore, advancements in personalized medicine, improved stem cell banking infrastructure, and increasing government support for regenerative medicine research are expanding the adoption of stem cell therapies across healthcare systems worldwide.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Services
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Allogeneic
    • 4.1.2 Autologous
    • 4.1.3 Syngeneic
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Adult Stem Cells
    • 4.2.2 Embryonic Stem Cells
    • 4.2.3 Induced Pluripotent Stem Cells
    • 4.2.4 Hematopoietic Stem Cells
    • 4.2.5 Mesenchymal Stem Cells
    • 4.2.6 Neural Stem Cells
    • 4.2.7 Amniotic Stem Cells
    • 4.2.8 Others
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Regenerative Medicine
    • 4.3.2 Orthopedic
    • 4.3.3 Neurology
    • 4.3.4 Cardiovascular
    • 4.3.5 Oncology
    • 4.3.6 Hematology
    • 4.3.7 Wound Healing
    • 4.3.8 Diabetes
    • 4.3.9 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cell Acquisition
    • 4.4.2 Cell Production
    • 4.4.3 Cryopreservation
    • 4.4.4 Expansion and Sub-Culture
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biotechnology Companies
    • 4.5.5 Others
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 In-Vivo
    • 4.6.2 Ex-Vivo
    • 4.6.3 Others
  • 4.7 Market Size & Forecast by Services (2020-2035)
    • 4.7.1 Stem Cell Banking
    • 4.7.2 Stem Cell Processing
    • 4.7.3 Stem Cell Characterization
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Preclinical
    • 4.8.2 Clinical Trials
    • 4.8.3 Commercialization
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 Invasive
    • 4.9.2 Non-Invasive
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 Technology
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Services
      • 5.2.1.8 Stage
      • 5.2.1.9 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 Technology
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Services
      • 5.2.2.8 Stage
      • 5.2.2.9 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 Technology
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Services
      • 5.2.3.8 Stage
      • 5.2.3.9 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 Technology
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Services
      • 5.3.1.8 Stage
      • 5.3.1.9 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 Technology
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Services
      • 5.3.2.8 Stage
      • 5.3.2.9 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 Technology
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Services
      • 5.3.3.8 Stage
      • 5.3.3.9 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 Technology
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Services
      • 5.4.1.8 Stage
      • 5.4.1.9 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 Technology
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Services
      • 5.4.2.8 Stage
      • 5.4.2.9 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 Technology
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Services
      • 5.4.3.8 Stage
      • 5.4.3.9 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 Technology
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Services
      • 5.4.4.8 Stage
      • 5.4.4.9 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 Technology
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Services
      • 5.4.5.8 Stage
      • 5.4.5.9 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 Technology
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Services
      • 5.4.6.8 Stage
      • 5.4.6.9 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 Technology
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Services
      • 5.4.7.8 Stage
      • 5.4.7.9 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 Technology
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Services
      • 5.5.1.8 Stage
      • 5.5.1.9 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 Technology
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Services
      • 5.5.2.8 Stage
      • 5.5.2.9 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 Technology
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Services
      • 5.5.3.8 Stage
      • 5.5.3.9 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 Technology
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Services
      • 5.5.4.8 Stage
      • 5.5.4.9 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 Technology
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Services
      • 5.5.5.8 Stage
      • 5.5.5.9 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 Technology
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Services
      • 5.5.6.8 Stage
      • 5.5.6.9 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 Technology
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Services
      • 5.6.1.8 Stage
      • 5.6.1.9 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 Technology
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Services
      • 5.6.2.8 Stage
      • 5.6.2.9 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 Technology
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Services
      • 5.6.3.8 Stage
      • 5.6.3.9 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 Technology
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Services
      • 5.6.4.8 Stage
      • 5.6.4.9 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 Technology
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Services
      • 5.6.5.8 Stage
      • 5.6.5.9 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Mesoblast
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Athersys
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Fate Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Pluristem Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Osiris Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 StemCells Inc
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cytori Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Vericel Corporation
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 BrainStorm Cell Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Caladrius Biosciences
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Gamida Cell
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Astellas Pharma
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 BioTime Inc
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 ReNeuron Group
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Cellular Biomedicine Group
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Lineage Cell Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Stempeutics Research
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Cynata Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Anterogen
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 ViaCyte
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us